X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STERLING BIOTECH - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STERLING BIOTECH IPCA LABS/
STERLING BIOTECH
 
P/E (TTM) x 27.5 -1.8 - View Chart
P/BV x 2.1 0.1 2,971.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   STERLING BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-17
STERLING BIOTECH
Dec-13
IPCA LABS/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs64311 6,123.8%   
Low Rs5033 14,788.2%   
Sales per share (Unadj.) Rs254.426.8 949.1%  
Earnings per share (Unadj.) Rs16.1-15.0 -107.4%  
Cash flow per share (Unadj.) Rs29.8-5.5 -545.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.654.9 354.5%  
Shares outstanding (eoy) m126.20267.87 47.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 868.6%   
Avg P/E ratio x35.7-0.5 -7,672.3%  
P/CF ratio (eoy) x19.2-1.3 -1,512.4%  
Price / Book Value ratio x2.90.1 2,325.3%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3001,862 3,883.6%   
No. of employees `00013.31.4 982.5%   
Total wages/salary Rs m6,960547 1,272.8%   
Avg. sales/employee Rs Th2,413.55,303.3 45.5%   
Avg. wages/employee Rs Th523.2403.8 129.5%   
Avg. net profit/employee Rs Th152.4-2,959.0 -5.2%   
INCOME DATA
Net Sales Rs m32,1067,181 447.1%  
Other income Rs m22643 529.8%   
Total revenues Rs m32,3327,223 447.6%   
Gross profit Rs m4,448947 469.7%  
Depreciation Rs m1,7302,543 68.0%   
Interest Rs m2414,377 5.5%   
Profit before tax Rs m2,703-5,931 -45.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675-1,924 -35.1%   
Profit after tax Rs m2,028-4,007 -50.6%  
Gross profit margin %13.913.2 105.1%  
Effective tax rate %25.032.4 77.0%   
Net profit margin %6.3-55.8 -11.3%  
BALANCE SHEET DATA
Current assets Rs m17,34014,335 121.0%   
Current liabilities Rs m9,55949,809 19.2%   
Net working cap to sales %24.2-494.0 -4.9%  
Current ratio x1.80.3 630.3%  
Inventory Days Days100403 24.9%  
Debtors Days Days57171 33.3%  
Net fixed assets Rs m20,77955,432 37.5%   
Share capital Rs m252268 94.2%   
"Free" reserves Rs m24,49913,935 175.8%   
Net worth Rs m24,55314,701 167.0%   
Long term debt Rs m3,5179,478 37.1%   
Total assets Rs m39,59573,988 53.5%  
Interest coverage x12.2-0.4 -3,444.3%   
Debt to equity ratio x0.10.6 22.2%  
Sales to assets ratio x0.80.1 835.5%   
Return on assets %5.70.5 1,144.0%  
Return on equity %8.3-27.3 -30.3%  
Return on capital %10.5-6.4 -163.2%  
Exports to sales %48.625.9 187.8%   
Imports to sales %14.20.2 8,379.7%   
Exports (fob) Rs m15,6171,860 839.7%   
Imports (cif) Rs m4,57112 37,467.2%   
Fx inflow Rs m15,6171,860 839.7%   
Fx outflow Rs m5,82825 23,413.8%   
Net fx Rs m9,7901,835 533.5%   
CASH FLOW
From Operations Rs m2,7641,719 160.8%  
From Investments Rs m-1,432-3,148 45.5%  
From Financial Activity Rs m-1,5911,426 -111.6%  
Net Cashflow Rs m-259-3 7,611.8%  

Share Holding

Indian Promoters % 45.9 33.9 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 9.9 255.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.4 39.3 44.3%  
Shareholders   36,892 21,482 171.7%  
Pledged promoter(s) holding % 2.1 55.9 3.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FULFORD INDIA  VENUS REMEDIES  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 21, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - UNICHEM LAB COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS